A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia
Latest Information Update: 07 Mar 2022
Price :
$35 *
At a glance
- Drugs ASC-09/ritonavir (Primary) ; Oseltamivir (Primary) ; Ritonavir (Primary)
- Indications Coronavirus infections; COVID 2019 infections; Pneumonia
- Focus Adverse reactions
- 09 Mar 2020 Status changed from not yet recruiting to recruiting.
- 24 Feb 2020 New trial record